Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dean F Bajorin

Showing results (101-110 of 169) with videos related to

Pageof 17
Sort By:
European Urology|August 6, 2020
Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial CarcinomaMin Yuen Teo, Jose Mauricio Mota, Karissa A Whiting, et al.
European Urology Focus|August 14, 2017
Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial CarcinomaSumit Isharwal, François Audenet, Esther Drill, et al.
Case Reports in Oncology|April 1, 2021
Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case ReportBrendan John Guercio, Gopa Iyer, Wajih Zaheer Kidwai, et al.
Science (New York, N.Y.)|August 28, 2012
Genome sequencing identifies a basis for everolimus sensitivityGopa Iyer, Aphrothiti J Hanrahan, Matthew I Milowsky, et al.
The Lancet. Oncology|May 29, 2021
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 studyArjun V Balar, Ashish M Kamat, Girish S Kulkarni, et al.
European Urology|August 22, 2024
Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 TrialRonald de Wit, David J Vaughn, Yves Fradet, et al.
Clinical Genitourinary Cancer|May 30, 2026
Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment in Metastatic Urothelial Cancer: A Randomized Phase II Study of Two Alternative Dosing SchedulesMichal Sternschuss, Charlie White, Colleen Quinlan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2018
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial CancerDavid J Vaughn, Joaquim Bellmunt, Yves Fradet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2020
Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in CancerSabine Topka, Zoe Steinsnyder, Vignesh Ravichandran, et al.
British Journal of Cancer|January 21, 2021
Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinomaMin Yuen Teo, Hikmat Al-Ahmadie, Kenneth Seier, et al.
Pageof 17

Showing results (101-110 of 169) with videos related to

Sort By:
Pageof 17
European Urology|August 6, 2020
Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial CarcinomaMin Yuen Teo, Jose Mauricio Mota, Karissa A Whiting, et al.
European Urology Focus|August 14, 2017
Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial CarcinomaSumit Isharwal, François Audenet, Esther Drill, et al.
Case Reports in Oncology|April 1, 2021
Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case ReportBrendan John Guercio, Gopa Iyer, Wajih Zaheer Kidwai, et al.
Science (New York, N.Y.)|August 28, 2012
Genome sequencing identifies a basis for everolimus sensitivityGopa Iyer, Aphrothiti J Hanrahan, Matthew I Milowsky, et al.
The Lancet. Oncology|May 29, 2021
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 studyArjun V Balar, Ashish M Kamat, Girish S Kulkarni, et al.
European Urology|August 22, 2024
Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 TrialRonald de Wit, David J Vaughn, Yves Fradet, et al.
Clinical Genitourinary Cancer|May 30, 2026
Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment in Metastatic Urothelial Cancer: A Randomized Phase II Study of Two Alternative Dosing SchedulesMichal Sternschuss, Charlie White, Colleen Quinlan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2018
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial CancerDavid J Vaughn, Joaquim Bellmunt, Yves Fradet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2020
Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in CancerSabine Topka, Zoe Steinsnyder, Vignesh Ravichandran, et al.
British Journal of Cancer|January 21, 2021
Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinomaMin Yuen Teo, Hikmat Al-Ahmadie, Kenneth Seier, et al.
Pageof 17